whereas AAAs >5.5 cm were associated with 1.75-fold higher risk (HR, 1.75; 95% CI, 1.26-2.45; P ¼ .001; Table) . For reintervention risk, there were no significant interactions or main effects of age or AAA diameter.
Objective: We conducted a large, multi-institutional study to assess the complications in patients undergoing carotid body tumor (CBT) excision. Comparisons of outcomes were made based on a traditional measure, Shamblin classification, and a new measure, distance to the base of skull (BOS).
Methods: A standardized database by a consortium of 14 institutions was used to assess patients who underwent surgical excision of CBT after cross-sectional imaging and subsequent assignment of Shamblin classification during a 10-year period (2004 to 2014). All CBT measurements were made using computed tomography/magnetic resonance imaging or ultrasound imaging, or both. Distance to BOS was the measurement on imaging from the top of the CBT to the BOS. CBT volume was calculated by ellipsoid approximation using two diameters measured from imaging.
Results: A total of 302 CBTs were excised in 293 patients (73% female; mean age, 52 years); 34% were Shamblin I, 42% Shamblin II, and 24% Shamblin III. The mean diameter was 3.8 cm (range, 1-11.3 cm), and mean volume was 25 cm 3 (range, 0.1-205 cm 3 ). Twenty-three percent had cranial nerve (CN) injuries. Patients with higher Shamblin class had more bleeding, temporary CN injuries, and vascular reconstruction (Table) . Shorter distance to BOS was associated with increased bleeding (P ¼ .02) and permanent CN injury (P ¼ .002). Patients with and without embolization (EMB), 22% and 78%, respectively, had no difference in CBT size, but EMB patients had significantly shorter distance to BOS (2.3 vs 3.7 cm; P ¼ .001). After adjusting for tumor size and distance to BOS, EMB was not associated with decreased bleeding (mean estimated blood loss, 209 vs 257 mL; P ¼ .78); however, it was associated with increased operative time (192 vs 141 minutes; P ¼ .01) and CN injuries (22% vs 13%; P ¼ .003). 
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Objective: The autogenous arteriovenous fistula (AVF) has been shown to be superior to the arteriovenous graft (AVG) with respect to cost, complications, and primary patency. Therefore, the National Kidney Foundation-Kidney Disease Outcomes Quality Initiative guidelines recommend reserving AVGs for patients who do not have adequate superficial venous anatomy to support AVF placement. The brachial artery-brachial vein AVF (BVAVF) has emerged as an alternative. However, there are limited data comparing BVAVF and AVG in patients who are otherwise not candidates for a traditional AVF.
Methods: A retrospective review of all patients who received BVAVF from July 2009 to July 2014 was performed. Patients who received an AVG and matched for age, gender, diabetes, and superficial venous anatomy were compared with the BVAVF group. Patient demographic data, operative details, and subsequent follow-up were collected. BVAVFs were performed with a two-stage approach with an initial arteriovenous anastomosis, followed by delayed superficialization or transposition. Comparisons were performed using the Student t-test and c 2 test as appropriate. Our primary outcome measure was patency at 1 year.
Results: Thirty-one patients underwent BVAVF during the study period. There were 40 patients in our matched AVG group. There was no difference in age, gender, diabetes, prior hemodialysis access, or absence of usable superficial vein between the two groups. The median days to cannulation from the initial operation was 141 in the BVAVF group and 30 in the AVG group (P < .001). More patients required interventions to maintain or re-establish patency in the AVG group than in the BVAVF group (35.0% vs 9.7%; P ¼ .013). Assisted primary patency at 1 year was superior in the BVAVF group (65.5% vs 40.6%; P ¼ .018). Functional assisted primary patency at 1 year was also superior in the BVAVF group (48.1% vs 21.6%; P ¼ .040). Functional secondary patency at 1 year was similar (BVAVF, 55.5% vs AVG, 48.6%; P ¼ .62).
Conclusions: BVAVFs had higher primary patency than AVGs, whereas secondary patency was similar. These findings support the use of BVAVFs as a viable alternative to AVGs in patients with inadequate superficial venous anatomy. The decision to perform a BVAVF must be weighed against the delay in functional maturation expected compared with an AVG.
